Morga A, Zimmermann L, Valluri U, Siddiqui E, McLeod L, Bender RH. Validation and application of thresholds to define meaningful change in vasomotor symptoms frequency: analysis of pooled SKYLIGHT 1 and 2 data. Adv Ther. 2024 May 22. doi: 10.1007/s12325-024-02849-2
Bektas M, Bell T, Khan S, Tumminello B, Fernandez MM, Heyes C, Oton AB. Desmoid tumors: a comprehensive review. Adv Ther. 2023 Sep;40(9):3697-722. doi: 10.1007/s12325-023-02592-0.
Ervin C, Norcross L, Mallya UG, Fehnel S, Mittleman RS, Webster M, Haqq AM, Haws RM. Interview-based patient- and caregiver-reported experiences of hunger and improved quality of life with setmelanotide treatment in bardet-biedl syndrome. Adv Ther. 2023 May;40(5):2394-411. doi: 10.1007/s12325-023-02443-y
Kim N, Brown TM, Burudpakdee C, Kanu C, Woodard K, Fehnel S, Morrison C, Nadglowski J, Nadolsky K, Kolotkin RL. Development of an assessment tool for completion by patients with overweight or obesity. Adv Ther. 2023 Jan;40(1):174-93. doi: 10.1007/s12325-022-02334-8
Gerbasi ME, Goss D, Petrillo J, Nejati M, Lewis S. Patient experiences in essential tremor: mapping functional impacts to existing measures using qualitative research. Poster presented at the 2023 International Congress of Parkinson's Disease and Movement Disorders; August 27, 2023. Copenhagen, Denmark. [abstract] Mov Disord. 2023; 38(Suppl 1).
Serbin M, Sutphin J, Leach C, Mansfield C, Yonan C, Klepitskaya O, Sheehan M, Donnelly A. Evaluating patients' preferences for parkinson's disease treatments. Poster presented at the MDS Virtual Congress 2021; September 17, 2021. [abstract] Mov Disord. 2021 Sep; 36(S1).
Merdan S, Barnett CL, Denton BT, Montie JE, Miller DC. OR practice–data analytics for optimal detection of metastatic prostate cancer. Oper Res. 2021 May;69(3):2-4. doi: 10.1287/opre.2020.2020
Serbin M, Odak S, Macahilig C, Joshi N, Shah A, Ng X, Olson K, Liang G, Klepitskaya O, Yonan C. Motor fluctuations in a real‐world sample of patients with parkinson's disease. Poster presented at the MDS Virtual Congress 2020; September 2020. [abstract] Mov Disord. 2020 Sep 11; 35(Suppl 1):S142. doi: 10.1002/mds.28268
Serbin M, Odak S, Macahilig C, Joshi N, Shah A, Ng X, Olson K, Liang G, Klepitskaya O, Yonan C. Real-world healthcare resource utilization in patients with parkinson's disease and motor fluctuations. Poster presented at the 2020 MDS Virtual Congress; September 2020. [abstract] Mov Disord. 2020 Sep; 35(Suppl 1):S142.
Thach A, Sutphin J, Coulter J, Mansfield C. A discrete-choice experiment evaluating preferences for on-demand treatments for patients with Parkinson's Disease and “OFF” episodes. Poster presented at the MDS Virtual Congress 2020; September 11, 2020. [abstract] Mov Disord. 2020 Sep; 35(S1):S427. doi: 10.1002/mds.28268
Thach A, Coulter J, Leach C, Sutphin J, Mansfield C. On-demand treatment preferences of patients with Parkinson's Disease and “OFF” episodes: heterogeneity across patient subgroups. Poster presented at the MDS Virtual Congress 2020; September 11, 2020. [abstract] Mov Disord. 2020 Sep; 35(S1):S427-8. doi: 10.1002/mds.28268
Martin S, Chen K, Harris N, Vera-Llonch M, Krasner A. Development of a patient-reported outcome measure for chronic hypoparathyroidism. Adv Ther. 2019 Aug;36(8):1999-2009. doi: 10.1007/s12325-019-00999-2
Purser MF, Mladsi DM, Beckman A, Barion F, Forsey J. Expected budget impact and health outcomes of expanded use of vagus nerve stimulation therapy for drug-resistant epilepsy. Adv Ther. 2018 Oct;35(10):1686-96. doi: 10.1007/s12325-018-0775-0.
Ervin CM, Reasner DS, Hanlon JT, Fehnel SE. Exploring the diabetic gastroparesis patient experience: patient exit interviews. Adv Ther. 2017 Dec;34(12):2680-92. doi: 10.1007/s12325-017-0632-6
Stull DE, McBride D, Houghton K, Finlay AY, Gnanasakthy A, Balp MM. Assessing changes in chronic spontaneous/idiopathic urticaria: comparisons of patient-reported outcomes using latent growth modeling. Adv Ther. 2016 Feb;33(2):214-24. doi: 10.1007/s12325-016-0282-0
Hess LM, Rajan N, Winfree K, Davey P, Ball M, Knox H, Graham C. Cost analyses in the US and Japan: a cross-country comparative analysis applied to the PRONOUNCE trial in non-squamous non-small cell lung cancer. Adv Ther. 2015 Dec 9;32(12):1248-62. doi: 10.1007/s12325-015-0270-9
Kitchen H, Rofail D, Heron L, Sacco P. Cognitive impairment associated with schizophrenia: a review of the humanistic burden. Adv Ther. 2012 Feb;29(2):148-62.
Small M, Vickers AD, Anderson P, Kay S. The patient-physician partnership in asthma: real-world observations associated with clinical and patient-reported outcomes. Adv Ther. 2010 Sep;27(9):591-9. doi: 10.1007/s12325-010-0054-1
Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. Mov Disord. 2010 Mar 15;25(4):474-80.
Edin HM, DiBenedetti D, Hill CD. Adherence among patients with Parkinson's Disease taking ropinirole immediate release at least three times daily. Poster presented at the Movement Disorders Society; June 13, 2008. [abstract] Mov Disord. 2008; 23:S344-5.
Hagell P, Whalley D, McKenna SP, Lindvall 0. Health status measurement in Parkinson's disease: validity of the PDQ-39 and Nottingham Health Profile. Mov Disord. 2003 Jul 1;18(7):773-83.